PTO/SB/21 (02-04)
006 OMB 0651-0031

	Under the Panentiark Reduction Ast as 400	.	U.S. Pa	Approved for use through 07/31/2006. OMB 065 Itent and Trademark Office; U.S. DEPARTMENT OF COMN	MERCE/
Λ	(PE)	5. no berso	Application Number	ction of information unless it displays a valid OMB control n 10/774,147	number.
	TRANSMITTAL		Filing Date	February 5, 2004	
ı	TORM		First Named Inventor	Sung-Ho RYU	-
3	(to be used to all correspondence after initial	ıl filing)	Art Unit	1653	
	(to be used bright correspondence after initial		Examiner Name	Robert A. WAX	
1	Total Number of Pages in This Submission	27	Attorney Docket Number	10050-03USA	

Total Number of Pages in This Submiss	27 744511551 10050-03USA							
ENCLOSURES (Check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Reque Information Disclosure Statem Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Funder 37 CFR 1.52 or	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks Total Number of Pages in Submission does not include references	closure(s) (please elow): 88 and copies of the cited references A1, Written Opinion and International Report; Copy of Office Action for oplication; Credit Card Payment for \$180; icard						
	NATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm or Joseph Hyosuk Kim Reg. No. 41,425 JHK Law Signature Date January 5, 2006	lee, Res.M. 56, 814							
January 5, 2000	CERTIFICATE OF TRANSMISSION/MAILING							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

January 5, 2006

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

the date shown below.

Typed or printed name

Signature

Harry Sung Lee

I hereby certify that on January 5, 2006, which is the date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Applicant: Sung-Ho RYU Serial No.: 10/774,147 Filed: February 5, 2004 Confirmation No.: 8753


Title: LEUKOCYTE STIMULATING

PEPTIDES

Examiner: Robert A. WAX

Art Unit: 1653

Attorney Docket No.: 10050-03USA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Documents:

US 2002/0072495 A1, CHERTOV et al., June 13, 2002

WO 03/031603 A1, MIAO et al., April 17, 2003

01/11/2006 MGEBREM1 00000050 10774147

01 FC:1806

180.00 GP

WO 03/031461 A2, LEKSTROM-HIMES et al., April 17, 2003

WO 02/058714 A2, BLASI et al., August 1, 2002

WO 00/31261 A2, KLEIN et al., June 2, 2000

WO 01/96373 A2, FRADKOVE et al., December 20, 2001

MARSHALL et al., "Involvement of Cytosolic Phospholipase A₂ and Secretory Phospholipase A₂ in Arachidonic Acid Release from Human Neutrophils", *The Journal of Immunology* (2000), 164: 2084-2091

LUKAS et al., "Identification of Novel Classes of Protein Kinase Inhibitors Using Combinatorial Peptide Chemistry Based on Functional Genomics Knowledge", *J. Med. Chem.* (1999), 42: 910-919

Retrieved from EBI accession no. AAM87955

HARMENBERG et al., "Search for Epitopic Sites of Antibodies to Germ Cell Alkaline Phosphatase", Cancer Communications (1991), 3(10/11): 305-311

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

Also submitted herewith are copies of the Written Opinion and International Preliminary Examination Report for corresponding International Application No. PCT/KR2004/000225 and Office Action for corresponding European Application No. 04 708 928.9. Please note that all of the above-listed references have been cited in the counterpart European Office Action, dated December 12, 2005, which corresponds to the instant application.

The Commissioner is authorized to charge JHK Law's Deposit Account No. 502486 for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a credit card payment form enclosed herewith and to credit any overpayment to said Deposit Account No. 502486.

January 5, 2006

Date

Joseph Hyosuk Kim, Ph.D.

Reg. No. 41,425

Attorney for Applicants

Respectfully submitted,

JHK Law

P.O. Box 1078

La Canada, CA 91012-1078

Telephone: (818) 249-8177

Facsimile: (818) 249-8277

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Complete if Known

10/774,147

February 5, 2004

Sung-Ho RYU

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995. sons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTOV

Sheet 1

INFORMATION DISCLOSURE STATEMENT

(Use as many

BY APPLICANT	Art Unit	1653
sheets as necessary)	Examiner Name	Robert A. WAX
of 1	Attorney Docket Number	10050-03USA

Filing Date

Application Number

First Named Inventor

	_		U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (ff known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 2002/0072495 A1	06-13-2002	CHERTOV et al.	whole document
·		US-			
		US-			
	<u> </u>	US-	•		
	i	US-			
	-	US-			
		US-			
	_	US-			
-		US-			
	ļ. —	US-			
		US-			

		FORE	IGN PATENT DOCU	<u>IMENTS</u>		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
	B1	WO 03/031603 A1	04-17-2003	MIAO et al.	whole document	
	B2	WO 03/031461 A2	04-17-2003	LEKSTROM-HINES et al.	whole document	
	B3	WO 02/058714 A2	08-01-2002	BLASI et al.	whole document	L
	B4	WO 00/31261 A2	06-02-2000	KLEIN et al.	whole document	
	B5	WO 01/96373 A2	12-20-2001	FRADKOV et al.	whole document	

Examiner		Date	
	•	Date	
Signature		l Considered	
٠ ١		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov.or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996 persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/774,147 INFORMATION DISCLOSURE Filing Date February 5, 2004 STATEMENT BY APPLICANT **First Named Inventor** Sung-Ho RYU Art Unit 1653 (Use as many sheets as necessary) **Examiner Name** Robert A. WAX Attorney Docket Number Sheet 10050-03USA

NON PATENT LITERATURE DOCUMENTS					
Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	C1	MARSHALL et al., "Involvement of Cytosolic Phospholipase A2 and Secretory Phospholipase A2 in Arachidonic Acid Release from Human Neutrophils", The Journal of Immunology (2000), 164: 2084-2091			
	C2	LUKAS et al., "Identification of Novel Classes of Protein Kinase Inhibitors Using Combinatorial Peptide Chemistry Based on Functional Genomics Knowledge", J. Med. Chem. (1999), 42: 910-919			
	СЗ	Retrieved from EBI accession no. AAM87955			
	C4	HARMENBERG et al., "Search for Epitopic Sites of Antibodies to Germ Cell Alkaline Phosphatase", Cancer Communications (1991), 3(10/11): 305-311			
•					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: